You are here
Medical City Plano, a HCA Healthcare Facility, Adopts iCAD’s Xoft Electronic Brachytherapy System for Treatment of Early-Stage Breast Cancer
Leading center becomes first in Texas to offer intraoperative radiation therapy with the advanced Xoft System to enhance patient care
NASHUA, N.H. and PLANO, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is now available at Medical City Plano. Operated by HCA Healthcare, the world-class medical facility in Plano, Texas is the first in the state to offer intraoperative radiation therapy (IORT) for the treatment of early-stage breast cancer using the Xoft System. The center is part of Medical City Healthcare, one of the region’s largest, most comprehensive healthcare providers in the Dallas-Fort Worth area.
“Bringing this revolutionary treatment to our community reinforces our commitment to offering patients superior care through cutting-edge technologies and supports our continued growth as a leading provider of compassionate healthcare,” said Charles Gressle, CEO of Medical City Plano. “We are proud to be the first facility in our area to provide Xoft IORT, a precise treatment option with significant advantages for women diagnosed with early-stage breast cancer, including shorter treatment times, fewer side effects, improved quality of life and overall better outcomes.”
IORT with the Xoft System uses a miniaturized x-ray source to deliver one precise, concentrated dose of radiation to a tumor site at the time of breast-conserving surgery (lumpectomy). The treatment can be completed in as little as eight minutes, making it possible for appropriately selected patients to replace six to eight weeks of traditional radiation therapy with a single treatment. The Xoft System is cleared by the U.S. Food and Drug Administration, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer, and gynecological cancers. It has been used to successfully treat more than 10,000 patients worldwide.
“We are pleased to partner with Medical City Plano to provide an important treatment option for breast cancer patients in the region. More than 18,000 women in Texas are expected to be diagnosed with breast cancer this year alone,” said Ken Ferry, CEO of iCAD. “Now breast surgeons and radiation oncologists at this renowned medical center can offer patients an effective, life-changing treatment option that minimizes their radiation exposure while also offering a better quality of life.”
A recent study established that IORT with the Xoft System is clinically proven to be the preferred method of treatment for early-stage breast cancer as compared to external beam radiation therapy due to significant cost savings, reduced radiation exposure and improved quality of life. The research demonstrated a direct cost savings of $630 million annually for the U.S. healthcare system and $10,500 per breast cancer patient annually over the lifetime of a patient.
The new IORT treatment solution with the Xoft System will be available along with additional breast care services and procedures at the Sarah Cannon Cancer Institute at Medical City Plano. To schedule a consultation with a breast care specialist at the Sarah Cannon Cancer Institute at Medical City Plano, please call 1-855-665-8627.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
About Medical City Plano
Medical City Plano is a full-service, 513 bed, acute care facility with more than 2,000 employees and 1,400 physicians representing more than 70 specialties and subspecialties. Accredited by The Joint Commission, Medical City Plano is a Level I Trauma Center with a Burn and Reconstructive Center, a Comprehensive (Level I) Stroke Center, a Level III NICU and Collin County’s first Chest Pain Accredited hospital. Magnet® designated for nursing excellence, Medical City Plano is part of Medical City Healthcare. For more information: visit MedicalCityPlano.com or follow us on Facebook and Twitter.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2017, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
ARPR, on behalf of iCAD, Inc.
Paul Barren, (855) 300-8209
Medical City Plano
Melissa Sauvage, Director of Community and Public Relations, (972) 519-1568
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568